Monitor this situation.

Unsubscribe anytime.

[SITUATION] · [QUIET] · [HEALTH]

4 clusters · 58 sources · 37 days · First seen about 2 months ago · Last updated 18 days ago

Bundibugyo Ebola vaccine trials

Overview

Clinical efforts to address the Bundibugyo Ebola outbreak in the Democratic Republic of the Congo (DRC) continue to expand. The outbreak, which has seen infections surpass 4,000 cases, has prompted the WHO and Africa CDC to declare a public-health emergency of international concern.

In Canada, Moderna’s Phase 1 trial for its mRNA-1469 vaccine began on 3 August, with the first participant dosed in Truro, Nova Scotia. The study, which includes sites in Halifax and Toronto, aims to enroll approximately 80 healthy adults to assess safety and immune response. Moderna has committed to providing at least 500,000 doses to low- and middle-income countries at access-pricing if licensed.

In the DRC, NanoViricides has received regulatory approval from the Congolese Pharmaceutical Regulatory Authority (ACOREP) to begin Phase 2 trials for its NV-387 treatment, which utilizes an oral gummy formulation.

Furthering vaccine development, the Coalition for Epidemic Preparedness Innovations (CEPI) has pledged up to $16.5 million to the African biopharmaceutical company Minapharm Group. This funding will support a vaccine candidate designed by ProBioGen that utilizes the MVA-CR19 modified vaccinia Ankara platform. This candidate is the fifth Bundibugyo-specific vaccine supported by CEPI and is designed to induce both B- and T-cell responses to aim for long-lasting immunity.

While existing vaccines for the Zaire strain may offer some cross-protection, the Bundibugyo strain remains rare and currently lacks approved specific treatments.

Entities

Democratic Republic of the Congo · Coalition for Epidemic Preparedness Innovations · Health Canada · Moderna · Minapharm Group

Claims

What the coverage asserts, and how many sources carry each claim.

[● 19 SOURCES] Health Canada authorized the Phase 1 trial on July 30.
[● 17 SOURCES] The trial will enroll about 80 healthy adults at three Canadian sites – Truro, Halifax and Toronto.
[● 16 SOURCES] CEPI pledged up to $50 million to fund pre‑clinical work, the Phase 1 trial and manufacturing of additional doses.
[● 16 SOURCES] The World Health Organization and Africa CDC have declared the outbreak a public‑health emergency.
[● 13 SOURCES] The vaccine candidate is called mRNA‑1469.
[● 13 SOURCES] The Democratic Republic of the Congo outbreak has 3,748 confirmed cases and 1,657 deaths as of early August.
[● 13 SOURCES] Moderna plans to make at least 500,000 doses available to low‑ and middle‑income countries under access‑pricing terms if the vaccine is licensed.
[● 13 SOURCES] The first volunteers received the vaccine dose on Monday.
[● 11 SOURCES] Moderna began its first human trial of an experimental vaccine against Bundibugyo ebolavirus.

Timeline

18 days ago

[HEALTH] 3 sources
Minapharm Group receives $16.5M for Bundibugyo ebola vaccine
Minapharm Group will receive up to $16.5 million from CEPI to advance a Bundibugyo ebolavirus vaccine candidate toward human clinical trials to combat an outbreak in the Democratic Republic of the Congo.
about 1 month ago

[HEALTH] 2 sources
Ebola vaccine trials advance in DRC and Canada
Clinical trials for Ebola treatments are advancing, with NanoViricides starting Phase 2 in the DRC and Moderna launching a Phase 1 mRNA vaccine trial in Canada targeting the rare Bundibugyo strain.
about 2 months ago

[HEALTH] 53 sources
Moderna's Bundibugyo Ebola Vaccine Enters Phase 1 Trial in Canada
Moderna’s mRNA‑1469 Ebola vaccine began a Phase 1 trial in Canada, enrolling ~80 volunteers to test safety and immune response amid a DRC outbreak with ~3,748 cases and 1,657 deaths; CEPI backs the effort with
about 2 months ago

[HEALTH] 2 sources
Oxford Vaccine ChAdOx1 BDBV Administered to First Human Volunteer
Oxford’s ChAdOx1 BDBV Ebola vaccine was given to volunteer Ed Hunt, the first human test, targeting the Bundibugyo strain amid a DRC outbreak.

Sources

680news.com · acadienouvelle.com · bahrainbulletin.com · battlefordsnow.com · bolnews.com · ca.sports.yahoo.com · canadianaffairs.news · castanet.net · channelchek.com · consultantlive.com · ddw-online.com · dgabc.com.br · dnyuz.com · document.dk · eltiempomx.com · emirates247.com · entrevue.fr · estamosaqui.mx · freemalaysiatoday.com · g4media.ro · globaldiasporanews.com · globalnation.inquirer.net · gr.euronews.com · healthcare-newsdesk.co.uk · independent.co.uk · joemygod.com · kesq.com · keyt.com · kfgo.com · kitchener.citynews.ca · krmg.com · larongenow.com · memesita.com · mommygearest.com · nannews.ng · narcity.com · news1130.com · news18.com · newscentral.africa · panow.com · paparazzi.com.ar · primanews.org · realitatea.md · scientificamerican.com · statnews.com · stiripesurse.ro · stocktitan.net · thedailybell.com

This summary has been updated 8 times: see revision history